Instalab

Oxalobacter Formigenes Test Stool

Get an early read on whether your gut has the bacteria that help protect against calcium oxalate kidney stones.

Should you take a Oxalobacter Formigenes test?

This test is most useful if any of these apply to you.

Had a Calcium Oxalate Kidney Stone
If you have passed a stone before, this test reveals whether you still have the gut bacterium linked to 70% lower recurrence odds.
Taken Multiple Antibiotic Courses
Certain antibiotics can wipe out this bacterium for years. This test shows whether modern medicine may have stripped you of a natural defense.
Living with IBD or Cystic Fibrosis
Gut conditions dramatically lower colonization rates and raise oxalate absorption. This test checks whether that missing protection applies to you.
Optimizing Your Gut Microbiome
If you are investing in gut health, this adds a piece most microbiome panels miss: whether one of the most studied oxalate-protective bacteria is present.

About Oxalobacter Formigenes

Calcium oxalate stones are one of the most painful conditions you can experience, and most prevention advice focuses on what you drink and what you eat. There is another player most people never think about: a specific bacterium living in your gut that literally eats oxalate for a living.

When this bacterium is present, research links it to roughly 70% lower odds of recurrent calcium oxalate kidney stones. When it is absent, often because antibiotics wiped it out years earlier, your body has one fewer defense against oxalate accumulating in your urine and crystallizing into stones.

What This Bacterium Does

Oxalobacter formigenes (OF for short) is a normal resident of the large intestine that uses oxalate as its only source of carbon and energy. It takes oxalate from the food you eat and from the oxalate your own body produces, then breaks it down into harmless byproducts before it can be absorbed into your bloodstream and filtered out through your kidneys.

The less oxalate that makes it into your urine, the less raw material there is to form calcium oxalate crystals. That is the central reason researchers have spent four decades studying this one bacterium. It is also one of the few gut microbes where the connection between its presence and a specific human disease has been demonstrated in controlled feeding studies, not just association data.

Kidney Stone Risk

The most striking finding about OF comes from a case-control study of recurrent stone formers. People colonized with this bacterium had about 70% lower odds of being a recurrent calcium oxalate stone former compared to people without it. Smaller studies in stone formers consistently show that colonized individuals have fewer prior stone episodes and lower urinary oxalate than those without the bacterium.

Who Was StudiedWhat Was ComparedWhat They Found
Adults with a history of calcium oxalate stones (506 people)Colonized vs not colonizedAbout 70% lower odds of being a recurrent stone former if colonized
Healthy adults on a controlled low-calcium, moderate-oxalate diet (22 people)Colonized vs not colonizedRoughly 19 to 20% lower urinary oxalate if colonized
Healthy adults given a single oral dose of live Oxalobacter (22 people)Before vs after colonizationAverage 14% drop in urinary oxalate after colonization took hold

Sources: Kaufman et al. 2008; Jiang et al. 2011; Fargue et al. 2025. What this means for you: if you have had even one calcium oxalate stone, whether this bacterium is living in your gut is one of the few modifiable factors that has been directly tied to your risk of forming another.

Hyperoxaluria and Related Conditions

Hyperoxaluria is the medical term for having too much oxalate in your urine. It can happen because your body absorbs more oxalate than usual, because you eat more, or because a gut condition disrupts fat absorption and causes oxalate to be absorbed in places it normally would not. OF colonization is linked to lower urinary oxalate in each of these situations.

In children with cystic fibrosis, the bacterium is almost entirely absent, and its absence strongly correlates with hyperoxaluria. In children with Crohn's disease, lack of OF colonization is one of the main risk factors for enteric hyperoxaluria. In inflammatory bowel disease more broadly, colonization is rare, and patients tend to have higher urinary oxalate.

In primary hyperoxaluria, a rare genetic condition where the liver produces excessive oxalate, oral OF has been tested as a therapy. Late-phase trials showed trends toward lower plasma oxalate and stabilization, though results have been mixed and not always statistically significant.

Why Most People Have Lost This Bacterium

Colonization with OF is present in only about 30 to 40% of healthy US adults. In remote indigenous populations, prevalence runs 60 to 80%. The gap is almost certainly driven by modern antibiotic use. Several common antibiotic classes, including macrolides, tetracyclines, chloramphenicol, and sulfa drugs, suppress the bacterium, and the effect can last for years after a single course.

In one population study, 55% of adults who had not taken sensitive antibiotics were colonized, compared to 17 to 36% of those who had. This is one plausible reason why kidney stone incidence has climbed alongside antibiotic use in developed countries.

Reference Ranges

This is an exploratory marker without universally agreed clinical cutpoints. No guideline body publishes reference ranges, and different labs use different detection methods (PCR, whole-genome sequencing, culture) that are not directly comparable. The research-derived ranges below come from population studies of healthy adults and stool colonization quantification, not from a standardized clinical assay.

StatusWhat It SuggestsTypical Finding
Detected (colonized)Active oxalate-degrading capacity in your gutFound in about 30 to 40% of US adults; 60 to 80% of remote indigenous populations
Not detectedEither truly absent or below the method's detection thresholdCommon after recent antibiotic exposure; more common in stone formers, IBD, and cystic fibrosis
Quantified abundanceLevels can vary within the same person between stool samplesRanges from under 5,000 to over one billion cells per gram of stool in colonized adults

Sources: Barnett et al. 2016; Pebenito et al. 2019; Prokopovich et al. 2007. Compare your results within the same lab over time for the most meaningful trend, since methods and detection thresholds differ significantly between labs.

When Results Can Be Misleading

A few situations can distort a single reading and lead you to the wrong conclusion:

  • High sample-to-sample variability: within the same person, stool OF can swing from undetectable to over one billion cells per gram. A single negative result does not definitively mean you lack the bacterium.
  • Recent antibiotic courses: antibiotics like clarithromycin (used to eradicate H. pylori), tetracyclines, and sulfa drugs can suppress detectable levels for months. If you tested during or within months of a course, a negative result may reflect temporary suppression rather than permanent absence.
  • Detection method differences: whole-genome shotgun sequencing is more sensitive than standard 16S rRNA profiling. A negative finding from a basic microbiome panel may simply mean the bacterium is below the method's detection threshold.
  • Other oxalate-degrading bacteria: some lab reports conflate broader oxalate-degrading gene signals with OF specifically. A positive for oxalate-degrading activity does not always mean this particular species is present.

Tracking Your Trend

Because OF levels vary between stool samples in the same person, a single test should not be treated as definitive. If you are actively trying to recolonize after antibiotics, or monitoring whether a lifestyle change is affecting your gut, retesting gives you a much better picture than any one reading.

A practical approach: get a baseline now to see where you stand. If the result is negative or low and you are making changes (dietary, probiotic, or post-antibiotic recovery), retest in 3 to 6 months. After that, annual testing is reasonable if you are actively managing kidney stone risk or have a condition like IBD or cystic fibrosis. The trend over several samples is far more informative than a single number.

Decision Pathway for Abnormal Results

A negative OF result on its own does not mean you are destined to form stones. It becomes actionable when combined with other evidence of oxalate risk. If you test negative, consider pairing this result with a 24-hour urine collection that measures oxalate, calcium, citrate, uric acid, and volume. That panel tells you whether your urine chemistry is actually showing elevated lithogenic risk right now.

If your urinary oxalate is high and OF is absent, that pattern is worth discussing with a urologist or nephrologist, particularly if you have had a stone, have IBD, have had bariatric surgery, or have cystic fibrosis. If you have had kidney stones and want a complete workup, a stone-forming specialist can help you interpret OF alongside other factors (dietary analysis, family history, imaging, and full metabolic stone panel) to build a targeted prevention plan.

One important caveat: this is still an emerging marker. Even colonized individuals form stones, and many uncolonized people never do. Treat the result as one piece of a larger risk picture, not a verdict.

What Moves This Biomarker

Evidence-backed interventions that affect your Oxalobacter Formigenes level

Decrease
Take oral antibiotics (macrolides, tetracyclines, sulfa drugs, chloramphenicol, rifampin, metronidazole)
Several antibiotic classes sharply suppress Oxalobacter colonization, and the effect can last for months to years after a single course. In a US adult study, colonization was present in 55% of people with no recent sensitive-antibiotic exposure, compared to 17 to 36% in those who had been exposed. Because losing this bacterium has been linked to higher urinary oxalate and higher recurrent stone risk, the drop matters for long-term kidney stone risk even if the antibiotic was taken for an unrelated infection.
MedicationStrong Evidence
Increase
Take live Oxalobacter formigenes (oral probiotic or investigational biotherapeutic)
A single oral dose of live Oxalobacter formigenes safely induced gut colonization in healthy adults and produced an average 14% drop in urinary oxalate. In separate trials for primary hyperoxaluria, oral Oxalobacter (Oxabact) showed trends toward lower plasma oxalate, though results were not always statistically significant. Baseline oxalate-degrading gene abundance predicts how well you respond to this therapy, so the effect is not uniform across individuals.
SupplementStrong Evidence
Decrease
Complete an H. pylori eradication antibiotic course (typically including clarithromycin and amoxicillin)
Treatment for H. pylori infection, which uses a multi-drug antibiotic regimen, was linked to persistently reduced Oxalobacter colonization in a 31-person cohort. The colonization drop outlasts the treatment itself and may raise your long-term risk of hyperoxaluria and recurrent kidney stones. If you are prescribed H. pylori eradication therapy, this side effect on your gut oxalate-degrading capacity is worth knowing about.
MedicationStrong Evidence
Increase
Eat a diet with regular oxalate-containing foods (spinach, nuts, beets, chocolate, tea)
Colonization and abundance of Oxalobacter tend to rise somewhat with higher dietary oxalate intake, because oxalate is this bacterium's fuel source. The effect on urinary oxalate is mixed: colonization lowers urinary oxalate on a controlled low-calcium, moderate-oxalate diet, but deliberately eating more oxalate to feed the bacterium is not a proven stone-prevention strategy, since it also raises the oxalate load your kidneys have to handle.
DietModest Evidence

Frequently Asked Questions

References

26 studies
  1. Daniel S, Moradi L, Paiste H, Wood KD, Assimos D, Holmes R, Nazzal L, Hatch M, Knight JApplied and Environmental Microbiology2021
  2. Liu M, Koh H, Kurtz ZD, Battaglia TW, Pebenito a, Li H, Nazzal L, Blaser MMicrobiome2017
  3. Mehta M, Goldfarb D, Nazzal LInternational Journal of Surgery2016
  4. Joshi S, Goldfarb DCurrent Opinion in Nephrology & Hypertension2019
  5. Prokopovich S, Knight J, Assimos D, Holmes RThe Journal of Urology2007